Vanessa Biotech has been granted regulatory approval from the Ghana FDA to conduct Phase 2 clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug.
The Phase 2 study will be conducted during the current rainy season by the University of Ghana’s research team lead by Prof. Ernest Kenu as Principal Investigator.
The drug will be studied for the innovative treatment of severe diarrhea of cholera, heralding a pipeline of drugs developed in hopes of neutralizing the lethal diarrhea of cholera as well as rotaviral diarrhea and traveler’s diarrhea.